Comparison of Gatifloxacin Versus Levofloxacin in the Treatment of Adults with Bacterial Infections: A Double-Blind, Randomized Trial in China

P. Hu,Z. Yuan,X. D. Zhou,E. Q. Xiong,G. S. Qian,H. He,Z. H. Peng,H. Ren
DOI: https://doi.org/10.1016/j.ijid.2008.05.1048
IF: 12.073
2008-01-01
International Journal of Infectious Diseases
Abstract:Objectives: Bacterial infections are a serious health problem worldwide. We compared the efficacy and safety of gatifloxacin, a new 8-methoxy fluoroquinolone, with that of levofloxacin in the treatment of bacterial infections. Methods: A randomized controlled multicentre clinical trial was conducted, with levofloxacin serving as the control drug. A total of 506 patients were enrolled in the study, 254 in the gatifloxacin group and the other 252 in the levofloxacin group. Results: The cure rates of gatifloxacin and levofloxacin were 84.46% and 82.73%, and the overall efficacy rates were 96.41% and 95.58% respectively. The bacterial clearance rates were 95.52% in gatifloxacin group vs 93.69% in levofloxacin group. The adverse drug reaction rates of gatifloxacin and levofloxacin were 10.63% and 10.71% respectively. There was no statistically significant difference between the two groups. The results of in vitro activities of gatifloxacin and other 4 antibacterial agents showed that gatifloxacin had good activities against Staphylococcus spp. and was more potent than those of levofloxacin, sparfloxacin, ciprofloxacin and cefotaxime. The activities of gatifloxacin against Streptococcus spp. were generally higher than those of levofloxacin, sparfloxacin, ciprofloxacin, and similar to those of cefotaxime. The activities of gatifloxacin against Gram-negative organisms were similar to or better than the other antibacterial agents. Conclusion: Gatifloxacin is an effective and on the basis of this trial, a safe broad-spectrum antibacterial agent for the treatment of bacterial infections.
What problem does this paper attempt to address?